Investing.com -- Mineralys Therapeutics Inc Nasdaq Mlys shares rose 4.7 in Monday trade after the company reported long-term results from its Transform-HTN trial showing lorundrostat demonstrated sustained blood pressure
Why Is Mineralys Therapeutics, Inc. (MLYS) Stock Down Today?
Updated Nov 22, 2026 11:08 AM ET ยท Prev Close $14.16
Session Regime & Catalyst Assessment
68% Signal ConvictionMineralys Therapeutics, Inc. Pulling Back 3.53% on 0.70x Relative Volume
Mineralys Therapeutics, Inc. (MLYS) is pulling back 3.53% (-$0.50) to $13.66 on 0.70x average session volume. Relative to benchmarks, MLYS is trading in line with the S&P 500 (+0.11% alpha). 14-day RSI stands at 28.7, keeping momentum in a oversold regime.
Investing.com -- Mineralys Therapeutics Inc Nasdaq Mlys shares rose 4.7 in Monday trade after the company reported long-term results from its Transform-HTN trial showing lorundrostat demonstrated sustained blood pressure
Price ($13.66) trades relative to 20-day SMA ($16.53) and 50-day SMA ($21.12).
Market & Sector Relative Strength
MLYS trading in line with the S&P 500 (+0.11% alpha)Recent MLYS Catalyst Headlines
Verified WireIn the largest long-term hypertension trial of an aldosterone synthase inhibitor to date, lorundrostat demonstrated sustained reduction in automated office systolic blood pressure AOSBP of 17.8 mmHg at Week 48 from Launc
Radnor, Pa., Nov. 06, 2026 Globe Newswire -- Mineralys Therapeutics, Inc. Nasdaq MLYS , a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comor
Mineralys Therapeutics Inc MLYS showcased robust lorundrostat efficacy and advanced commercial preparations while reporting a widened net loss ahead of its December PDUFA date.
1โ3 Day Expected Range & Key Level
48% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $13.57 (session support) for directional breakout confirmation.
Technical Regime (MLYS)
BEARISH MA TRENDRetail & Crowd Sentiment
BullishStockTwits messages suggest bullish sentiment towards $MLYS, with mentions of Stifel's positive comments on Lorundrostat and potential M&A activity.
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP โฆ
Get Instant MLYS Catalyst Alerts
Receive an email alert when MLYS triggers an unusual volume breakout, options sweep, or rating shift.
MLYS Session & Catalyst FAQ
Why is MLYS stock down today?
Mineralys Therapeutics, Inc. (MLYS) is pulling back 3.53% (-$0.50) to $13.66 on 0.70x average session volume. Relative to benchmarks, MLYS is trading in line with the S&P 500 (+0.11% alpha). 14-day RSI stands at 28.7, keeping momentum in a oversold regime.
Is MLYS stock a buy or sell right now?
Today's session carries a 68% catalyst conviction score on 0.70x relative volume (low participation). Our multi-factor model currently rates MLYS as HOLD. Review full valuation, quality, and timing signals on the MLYS Buy or Sell Decision Brief โ
What is MLYS's intrinsic value and expected trading range?
At $13.66, MLYS's modeled 1-to-3 session range is $12.91 โ $14.41, with a key inflection level at $13.57 (session support). Compare current price against multi-year cash flow projections in the MLYS Intrinsic Value & DCF Model โ and Market Cycle Phase Tracker โ
What do RSI and moving averages signal for MLYS?
RSI at 28.7 indicates oversold conditions โ watch for mean-reversion support. MLYS trades at $13.66 relative to its 20-day SMA ($16.53) and 50-day SMA ($21.12), reflecting a bearish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.